Human Trial, page-244

Wow that link sends you down the rabbit hole! Looking at some earlier tests it looks like Combidex produced too many false negatives (24%) but I don't know the timeframe.

https://www.sciencedirect.com/topics/medicine-and-dentistry/superparamagnetic-iron-oxide-nanoparticle

But it led me onto this, a Swedish company Affibody Medical AB:

ABY-025 - Breast Cancer Imaging
ABY-025 provides a new non-invasive cost-effective
approach to diagnose global HER2-expression in
metastatic breast cancer patients using PET imaging.
Affibody is currently working together with academic
institutions to explore the clinical utility of ABY-025
further. A Nordic multicenter investigator led clinical
Phase II/III study with [68Ga] ABY-025 is currently
recruiting patients.
....

Projects in Preclinical Development
GE-226 – PET imaging
In September 2019, a strategic collaboration with GE
Healthcare to develop and commercialize Affibody®-
based PET imaging tracers, with initial focus on
HER2 was announced. The collaboration also
includes another project focusing on PD-L1, currently
in preclinical development.

The above were extracts from their investor reports (November 2020)

https://www.affibody.se/investor/interim-reports/

So GE Healthcare are putting multiple bets as you would expect. Of course this is for PET so radiation required.

For me there are both negative and positive things about GE. The negative is that if the PET way provides a solution to identifying HER2 metastatic breast cancer then GE will not be in such a rush to find another MRI/Magsense solution. The positive is that GE are keeping us in the frame as a possible viable solution also. We need some positive outcomes from our trial!